VAC4ALL
Vac4All is a biotech company that provides the development of vaccines against malaria disease.
VAC4ALL
Industry:
Biotechnology Health Care Manufacturing Non Profit Pharmaceutical
Founded:
2010-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.vac4all.org
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
OVH
Similar Organizations
vitaMK7
vitaMK7 is a biotech company that produces ingredients for nutrition, cosmetic, and personal care.
Official Site Inspections
http://www.vac4all.org
- Host name: cluster014.ovh.net
- IP address: 213.186.33.87
- Location: Saran France
- Latitude: 47.9531
- Longitude: 1.871
- Timezone: Europe/Paris
- Postal: 45770
More informations about "Vac4All"
Vac4All - Just another WordPress site
Our unique scientific strategy & approach used to discover our lead candidates ; A strategic alliance with Sanofi to safeguard registration and marketing; Lean management with a compact team of experienced in-house personnel; A large …See details»
About Us – WordPress - Vac4All
The World Health Organization (WHO) estimates that up to half of the world's population is at risk of malaria. Vac4All vaccines respond to the full spectrum of unmet medical needs, from those …See details»
Science & Pipeline – WordPress - Vac4All
Vac4All’s portfolio of candidate-vaccines, based on the antigens MSP3, LSA3 and LSA5, results from decades of research into human malaria immunity. By examining the types of clinical …See details»
Vac4All - Crunchbase Company Profile & Funding
Vac4All is a biotech company that provides the development of vaccines against malaria disease. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …See details»
Pierre Druilhe Profile | Special Programme for Research & Training …
[email protected]. Collaboration Network. Are you Pierre Druilhe? Edit your profile. WHO REGION. WHO European Region; COUNTRY OF NATIONALITY. ... The Special Programme …See details»
Vac4All - Drug pipelines, Patents, Clinical trials - Synapse
Explore Vac4All with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, Drug:Malaria vaccine (MSP3-LSP) (Vac4All).See details»
Vac4All - Overview, News & Similar companies | ZoomInfo.com
Who is Vac4All. Founded by Dr. Pierre Druilhe in 2010 using a combination of private and public funding, Vac4All is a biotech company entirely dedicated to the dev elopment of vaccines …See details»
Malaria vaccine (MSP3-LSP) (Vac4All) - Drug Targets
Nov 21, 2024 Malaria vaccine (MSP3-LSP) (Vac4All): a Immunostimulants Drug, Initially developed by Vac4All, Now, its global highest R&D status is Pending, Mechanism: Immunostimulants, Therapeutic Areas: Infectious Diseases. ...See details»
Resources – WordPress - vac4all.org
The World Health Organization (WHO) estimates that up to half of the world's population is at risk of malaria. In 2016, transmission was reported in more than 91 countries, across South-East …See details»
Pre-clinical assessment of novel multivalent MSP3 malaria vaccine ...
Background: MSP3 has been shown to induce protection against malaria in African children. The characterization of a family of Plasmodium falciparum merozoite surface protein 3 (MSP3) …See details»
High-level artemisinin-resistance with quinine co-resistance …
Oct 1, 2018 10 The Vac4All Initiative, 26 Rue Lecourbe, 75015, Paris, France. [email protected]. 11 Biomedical Parasitology Unit, Institut Pasteur, Paris, France. …See details»
Malaria vaccine (PfPEBS) (Vac4All) - Drug Targets ... - Patsnap
Malaria vaccine (PfPEBS) (Vac4All): a Immunostimulants Drug, Initially developed by Vac4All, Now, its global highest R&D status is Pending, Mechanism: Immunostimulants, Therapeutic …See details»
Safety, tolerability and immunogenicity of MSP3-CRM-Vac4All
Feb 12, 2024 A total of 42 healthy male and female participants aged 18 to 55 years will be enrolled and randomized into one of three cohorts. Three dose levels of a novel malaria …See details»
Contact Us – WordPress - vac4all.org
Vac4All recognizes and respects the privacy of our online visitors. Vac4All only collects personal information that website visitors share with us when contacting us. Any information collected …See details»
Evaluating Human Immune Responses for Vaccine Development in …
Vac4All Initiative, Paris, France Soulaima Chamat Laboratory of Immunology and Vector Born Diseases, Faculty of Public Health-Fanar, Lebanese University, Beirut, Lebanon ... Eric Prieur …See details»
Antibody-Dependent Cell-Mediated Inhibition (ADCI) of ... - PubMed
2 VAC4ALL, 26 Rue Lecourbe, Paris, 75015, France. [email protected]. PMID: 26450385 DOI: 10.1007/978-1-4939-2815-6_11 Abstract The ADCI assay aims to measure the ability of …See details»
Publications/Reports – WordPress - vac4all.org
Company Overview; Mission & Vision; Our Team; Our Partners; Our Investors; Science & PipelineSee details»
Pre-Clinical Assessment of Novel Multivalent MSP3 Malaria …
Dec 1, 2011 Background MSP3 has been shown to induce protection against malaria in African children. The characterization of a family of Plasmodium falciparum merozoite surface protein …See details»
Malaria vaccine (MSP3CRMV4All) - Vac4All - AdisInsight - Springer
May 4, 2023 Malaria vaccine MSP3-CRM-Vac4All/ Alhydrogel® is being developed by Vac4All, for the prevention of falciparum malaria in Africa. Clinical development tis Malaria vaccine …See details»
Pre-Clinical Assessment of Novel Multivalent MSP3 Malaria
* E-mail: [email protected]. These authors contributed equally to this work. Introduction Malaria caused by Plasmodium falciparum (P. falciparum) is one of infectious diseases with the …See details»